S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17

Cabaletta Bio News Headlines

$1.88
+0.07 (+3.87%)
(As of 05/17/2022 04:00 PM ET)
Add
Compare
Today's Range
$1.78
$1.91
50-Day Range
$1.22
$2.29
52-Week Range
$1.17
$14.95
Volume
134,753 shs
Average Volume
170,285 shs
Market Capitalization
$54.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.53
Get Cabaletta Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Cabaletta Bio Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CABA
News Sentiment

1.53

0.46

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CABA Articles
This Week

4

1

CABA Articles
Average Week



Cabaletta Bio (NASDAQ:CABA) News Headlines Today

SourceHeadline
finance.yahoo.com logoCabaletta Bio to Present at the H.C. Wainwright Global Investment Conference
finance.yahoo.com - May 17 at 9:10 AM
finance.yahoo.com logoCabaletta Bio Reports First Quarter 2022 Financial Results and Provides Business Update
finance.yahoo.com - May 12 at 10:32 AM
finance.yahoo.com logoCabaletta Bio to Present DSG3-CAART Clinical Data and MuSK-CAART Preclinical Data at Upcoming Scientific Meetings in May
finance.yahoo.com - May 2 at 8:39 PM
benzinga.com logoCLASS ACTION UPDATE for CABA, AI and MYPS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
benzinga.com - April 28 at 5:36 PM
baystreet.ca logoThe Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CABA, AI and ABBV
baystreet.ca - April 27 at 9:08 PM
benzinga.com logoThe Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CABA, SDIG and LILM
benzinga.com - April 26 at 11:06 PM
finance.yahoo.com logoIs Cabaletta Bio (NASDAQ:CABA) In A Good Position To Invest In Growth?
finance.yahoo.com - April 15 at 8:44 AM
finance.yahoo.com logoCabaletta Bio to Present at the 21st Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 6 at 10:59 AM
apnews.com logoROSEN, A LEADING LAW FIRM, Encourages Cabaletta Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CABA
apnews.com - March 24 at 7:10 AM
benzinga.com logoCABA Stock Investigation: Robbins LLP Investigates Cabaletta Bio, Inc. (CABA) on Behalf of Shareholders
benzinga.com - March 18 at 8:52 PM
benzinga.com logoMizuho Maintains Buy on Cabaletta Bio, Lowers Price Target to $20
benzinga.com - March 18 at 3:52 PM
benzinga.com logoRecap: Cabaletta Bio Q4 Earnings
benzinga.com - March 17 at 7:31 PM
finance.yahoo.com logoCabaletta Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
finance.yahoo.com - March 17 at 7:31 PM
benzinga.com logoInvestor Alert: Robbins LLP Reminds Investors that Cabaletta Bio, Inc. (CABA) is Being Sued for Misrepresentation
benzinga.com - March 11 at 2:45 AM
benzinga.com logoNOTICE: Cabaletta Bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – CABA
benzinga.com - March 7 at 11:36 PM
benzinga.com logoInvestor News: Robbins LLP Reminds Investors of the Lawsuit Against Cabaletta Bio, Inc. (CABA)
benzinga.com - March 6 at 10:17 AM
benzinga.com logoHAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Cabaletta Bio (CABA) Investors with Significant Losses of Opportunity to Lead Securities Class Action
benzinga.com - March 4 at 6:12 PM
finance.yahoo.com logoLab notes: Myonex acquires German drug business; Vallon receives Covid drug treatment patent
finance.yahoo.com - March 4 at 6:12 PM
apnews.com logoShareholder Action Notice: The Schall Law Firm Encourages Investors in Cabaletta Bio, Inc. with Losses of $100,000 to Contact the Firm
apnews.com - March 3 at 7:20 PM
benzinga.com logoSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Cabaletta Bio, Inc. with Losses of $100,000 to Contact the Firm
benzinga.com - March 3 at 4:12 AM
apnews.com logoINVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Cabaletta Bio, Inc. with Losses of $100,000 to Contact the Firm
apnews.com - March 1 at 11:40 PM
apnews.com logo(CABA) INVESTOR DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel About Leading Cabaletta Class Action
apnews.com - March 1 at 6:40 PM
benzinga.com logoBronstein, Gewirtz & Grossman, LLC Notifies Cabaletta Bio, Inc. (CABA) Investors of Class Action and Encourages Investors to Contact the Firm
benzinga.com - March 1 at 6:40 PM
marketwatch.com logoCabaletta Bio Gets Fast Track Designation for Autoantibody Receptor
marketwatch.com - March 1 at 6:40 PM
finance.yahoo.com logoU.S. Food and Drug Administration Grants Cabaletta Bio Fast Track Designation for MuSK-CAART
finance.yahoo.com - March 1 at 6:40 PM
finance.yahoo.com logoCabaletta Bio to Participate in the Cowen Virtual 42nd Annual Health Care Conference
finance.yahoo.com - February 28 at 12:36 PM
bizjournals.com logoLab Notes: Strata Skin Sciences makes acquisition; Cabaletta Bio promotes 2 executives
bizjournals.com - January 14 at 3:38 PM
finance.yahoo.com logoCabaletta Bio Strengthens Executive Leadership Team with Promotions of Gwendolyn Binder, Ph.D. to President of Science and Technology and Arun Das, M.D. to Chief Business Officer
finance.yahoo.com - January 11 at 9:22 AM
finance.yahoo.com logoCabaletta Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 10 at 8:16 AM
benzinga.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cabaletta Bio, Inc. - CABA
benzinga.com - January 6 at 11:22 PM
lse.co.uk logoOxford Biomedica wins new agreement for LentiVector platform
lse.co.uk - January 5 at 10:22 AM
finance.yahoo.com logoDown 63.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Cabaletta Bio, Inc. (CABA)
finance.yahoo.com - January 4 at 1:23 PM
finance.yahoo.com logoCabaletta Bio to Present at the H.C. Wainwright BioConnect Conference
finance.yahoo.com - January 3 at 10:15 AM
marketwatch.com logoCabaletta Bio Shares Plummet After Lead Program Study Update >CABA
marketwatch.com - December 17 at 12:06 AM
benzinga.com logoMorgan Stanley Maintains Overweight on Cabaletta Bio, Lowers Price Target to $15
benzinga.com - December 16 at 12:54 AM
markets.businessinsider.com logoCabaletta Bio's Cell Therapy Fails To Show Activity At Low Doses In Skin Blistering Disorder
markets.businessinsider.com - December 14 at 2:05 PM
finance.yahoo.com logoCabaletta Bio Reports Top-line Biologic Activity Data from Two Lowest Dose Cohorts in DesCAARTes™ Trial in Patients with Mucosal Pemphigus Vulgaris
finance.yahoo.com - December 14 at 9:03 AM
finance.yahoo.com logoCabaletta Bio to Participate in Upcoming Investor Conferences in November
finance.yahoo.com - November 9 at 6:06 PM
finance.yahoo.com logoCabaletta Bio Expands Executive Leadership Team with Appointments of Samik Basu, M.D. to Chief Scientific Officer and Heather Harte-Hall, MSc. to Chief Compliance Officer
finance.yahoo.com - November 9 at 1:05 PM
finance.yahoo.com logoWall Street Analysts Predict a 52% Upside in Cabaletta Bio, Inc. (CABA): Here's What You Should Know
finance.yahoo.com - November 3 at 2:16 PM
msn.com logoBRIEF-Cabaletta Bio Reports Clinical Data From Third Dose Cohort In DesCAARTes Trial In Patients With mPV
msn.com - November 2 at 11:14 PM
finance.yahoo.com logoCabaletta Bio Reports Clinical Data from the Third Dose Cohort in DesCAARTes™ Trial in Patients with mPV
finance.yahoo.com - November 1 at 8:26 AM
finance.yahoo.com logoCabaletta Bio Reports Third Quarter 2021 Financial Results and Provides Business Update
finance.yahoo.com - November 1 at 8:26 AM
finance.yahoo.com logoHow Many Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Do Institutions Own?
finance.yahoo.com - October 17 at 2:17 PM
nasdaq.com logoWhat Kind Of Shareholders Hold The Majority In Cabaletta Bio, Inc.'s (NASDAQ:CABA) Shares?
nasdaq.com - October 6 at 12:41 PM
finance.yahoo.com logoCabaletta Bio to Present at the Chardan 5th Annual Genetic Medicines Conference
finance.yahoo.com - September 28 at 8:42 AM
finance.yahoo.com logoCabaletta Bio Announces Appointment of Michael Gerard as General Counsel
finance.yahoo.com - September 7 at 4:36 PM
finance.yahoo.com logoCabaletta Bio to Participate in Upcoming Investor Conferences in September
finance.yahoo.com - September 2 at 9:01 AM
finance.yahoo.com logoCabaletta Bio's Cell Therapy Shows Encouraging Safety Profile In Autoimmune Skin Disorder
finance.yahoo.com - August 18 at 4:57 PM
msn.com logoBRIEF-Cabaletta Bio Reports Clinical Data From The Second Dose Cohort In Descaartes Trial In Patients With MPV
msn.com - August 18 at 8:16 AM
Get Cabaletta Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.